Is DexCom a go-to health care stock? [Video]
|DexCom, Inc. is a global company headquartered in San Diego, California, that focuses on the development, manufacturing, and distribution of continuous glucose monitoring (CGM) systems for managing diabetes. These systems enable individuals with diabetes to monitor their blood glucose levels consistently throughout the day, aiding in effective diabetes management and treatment decision-making. With a strong international presence, DexCom serves customers worldwide, contributing significantly to advancements in diabetes care through its innovative CGM technology.
When there are recessionary risks healthcare companies can remain profitable as consumers understandably prioritize health care. DexCom has some impressive seasonal patterns outlined which have been found using the Seasonax screener feature.
Over the last 15 years, DexCom has gained 14 out of 15 times. With a very strong seasonal pattern and excellent annualized returns of over 115% and an average of 13.18%, the main question is if it is worth looking at DexCom as we head into the summer months.
Major Trade Risks: The major trade risk here is for stock-specific news to DexCom or if the seasonal pattern fails to hold up this year.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.